08:40 AM EDT, 10/15/2025 (MT Newswires) -- Avantor ( AVTR ) said Wednesday it has partnered with BlueWhale Bio to develop and scale manufacturing of cell-derived nanoparticle materials for CAR-T therapies.

The biotechnology research company said the collaboration will combine its bioprocessing and reagent production capabilities with BlueWhale's cell-derived nanoparticle platform Synecta to support the manufacture and production of materials used in CAR-T therapies.

The companies plan to produce GMP-grade CDNP materials to support this process.

Financial details of the partnership were not provided.

Shares of Avantor ( AVTR ) were up 1.6% in recent Wednesday premarket activity.